The role of amino acids in the modulation of cardiac metabolism during ischemia and heart failure

Current Pharmaceutical Design

Volumn 14, Issue 25, 2008, Pages 2592-2604

  Marazzi, Giuseppe ^a   Rosanio, Salvatore ^b   Caminiti, Giuseppe ^a   Dioguardi, Franceso Saverio ^c   Mercuro, Giuseppe ^d  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Amino acids; Cardiac metabolism; Heart failure; Myocardial ischemia

Indexed keywords

ACETYLCARNITINE; ARGININE; ASPARTIC ACID; BRANCHED CHAIN AMINO ACID; CARNITINE; CATECHOLAMINE DERIVATIVE; CREATINE; CREATINE PHOSPHATE; ENALAPRIL; ESSENTIAL AMINO ACID; FREE RADICAL; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; ISOPRENALINE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROPIONYLCARNITINE; PYRUVIC ACID; TAURINE; ZINC ASPARTATE;

ABSENCE OF SIDE EFFECTS; AMINO ACID ANALYSIS; ANTIOXIDANT ACTIVITY; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; ENERGY YIELD; EXERCISE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GENE FUNCTION; GLUTATHIONE METABOLISM; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HORMONE RESPONSE; HUMAN; IMMUNOMODULATION; INOTROPISM; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; NONHUMAN; NUCLEIC ACID SYNTHESIS; OXIDATIVE STRESS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIDE EFFECT; WEIGHT GAIN;

AMINO ACIDS; ANIMALS; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA;

EID: 57349122306     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786071227     Document Type: Review

References (159)

1. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol 1994; 19: 59-113.
2. Strauer BE. Cardiac energetics in clinical heart disease. Basic Res Cardiol 1987; 82(Suppl 2): 389-402.
3. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med 2007; 356: 1140-51.
4. Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott RS, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005; 179: 201-6.
5. Taegtmeyer H, King LM, Jones BJ. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 1998; 82: K54-60.
6. Leong HS, Brownsey RW, Kulpa JE, Allard MF. Glycolysis and pyruvate oxidation in cardiac hypertrophy - why so unbalanced. Comp Biochem Physiol Mol Integr Physiol 2003; 135: 499-513.
7. Sharma N, Okere IC, Brunengraber DZ, McElfresh TA, King KL, Sterk JP, et al. Regulation of pyruvate dehydrogenase activity and citric acid cycle intermediates during high cardiac power generation. J Physiol 2005; 562(2): 593-603.
8. Fosslien E. Review: Mitochondrial medicine - cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci 2003; 33: 371-95.
9. Mishra OP, Randis T, Ashraf QM, Delivoria-Papadopulos M. Hypoxia- induced bax and bcl-2 protein expression,caspase-9 activation, dna fragmentation, and lipid peroxidation in mitochondria of the cerebral cortex of newborn piglets: the role of nitric oxide. Neuroscience 2006; 141: 1339-49.
10. Sedlak TM, Snyder SH. Messenger molecules and cell death. therapeutic implications. JAMA 2006; 295: 81-9.
11. Pasini E, Aquilani R, Dioguardi FS. Amino acids: chemistry and metabolism in normal and hypercatabolic states. Am J Cardiol 2004; 93(Suppl): A3-5.
12. Pain VM, Albertse EC, Garlick PJ. Protein metabolism in skeletal muscle, diaphragm, and heart of diabetic rats. Am J Physiol 1983; 245: E604-10.
13. Bäckström T, Goiny M, Lockowandt U, Liska J, Franco-Cereceda A. Cardiac outflow of amino acids and purines during myocardial ischemia and reperfusion. J Appl Physiol 2003; 94: 1122-8.
14. Svedjeholm R, Ekroth R, Joachimsson PO, Ronquist G, Svensson S, Tyde'n H. Myocardial uptake of amino acids and other substrates in relation to myocardial oxygen consumption four hours after cardiac operations. J Thorac Cardiovasc Surg 1991; 101: 688-94.
15. Pasini E, Scarabelli TM, D'Antona G, Dioguardi FS. Effects of amino acid mixture on the isolated ischemic heart. Am J Cardiol 2004; 93(Suppl): A30-4.
16. Scognamiglio R, Negut C, Piccolotto R, Dioguardi FS, Tiengo A, Avogaro A. Effects of oral aminoacid supplementation on myocardial function in patients with type 2 diabetes mellitus. Am Heart J 2004; 147: 1106-12.
17. Lehninger A. Biochemistry. New York: Worth Publishers 1975; 71: 561.
18. Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest 1987; 80: 1-6.
19. Fukagawa NK, Minaker KL, Rowe JW, Goodman MN, Matthews DE, Bier DM, et al. Insulin-mediated reduction of whole body protein breakdown: dose-response effects of leucine metabolism in postabsorptive men. J Clin Invest 1985; 76: 2306-11.
20. Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS. Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J 2003; 4: 232-5.
21. Moulias R, Meaume S, Raynaud-Simon A. Sarcopenia, hypermetabolism and aging. Z Gerontol Geriatr 1999; 6: 425-32.
22. Muller M, Bottcher OS, Weselmann S, Boker K, Schwarze M, Von zur Muhlen A, et al. Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr 1999; 69: 1194-201.
23. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30: 527-32.
24. Song, D, O'Regan MH, and Phillis JW. Mechanisms of amino acid release from the isolated anoxic/reperfused rat heart. Eur J Pharmacol 1998; 351: 313-22.
25. Zemgulis V, Ronquist G, Bjerner T, Henze A, Waldenstrom A, Thelin S, et al. Energy-related metabolites during and after induced myocardial infarction with special emphasis on the reperfusion injury after extracorporeal circulation Acta Physiol Scand 2001; 171: 129-43.
26. Meijer AJ. Amino acids as regulators and components of nonproteinogenic pathways. J Nutr 2003; 133(Suppl 1): S2057-62.
27. Mudge GH, Mills RM, Taegtmeyer H, Gorlin R, Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Invest 1976; 58: 1185-92.
28. Brosnan JT, Krebs HA, Williamson DH. Effects of ischaemia on metabolite concentrations in rat liver. Biochem. J 1970; 117: 91-6.
29. Rovetto MJ, Lamberton WF, Neely JR. Mechanisms of glycolytic inhibition in ischemic rat hearts. Circ. Res 1975; 37: 742-51.
30. Brodan V, Fabian J, Andel M, Pechar J. Myocardial amino acid metabolism in patients with chronic ischemic heart disease. Basic Res Cardiol 1978; 73: 160-70.
31. Bittl JA, Shine KI. Protection of ischemic rabbit myocardium by glutamic acid. Am J Physiol 1983; 245: H406-12.
32. Choong YS, Gavin JB, Armiger LC. Effects of glutamic acid on cardiac finction and energy metabolism of rat heart durino ischemia and reperfusion. J Mol Cell Cardiol 1988; 20: 1043-51.
33. Bush LR, Warren RS, Mesh CL, Lucchesi BR. Comparative effects of aspartate and glutamate during myocardial ischemia. Pharmacology 1981; 23: 297-304.
34. Haas GS, DeBoer LWV, O'Keefe DD, Bodenhamer RM, Geffin GA, Drop LJ, et al. Reduction of postischemic myocardial dysfunction by substrate repletion during reperfusion. Circulation 1984; 70(3 Pt 2): I65-74.
35. Thomassen A, Nielsen TT, Bagger JP, Henningsen P. Effects of intravenous glutamate on substrate availability and utilization across the human heart and leg. Metab Clin Exp 1991; 40: 378-89.
36. Thomassen A, Nielsen TT, Bagger JP, Pedersen AK, Henningsen P. Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or Syndrome X. Am J Cardiol 1991; 60: 291-5.
37. Bolotin G, Raman J, Williams U, Bacha E, Kocherginsky M, Jeevanandam V. Glutamine improves myocardial function following ischemia-reperfusion injury. Asian Cardiovasc Thorac Ann 2007; 15: 463-7.
38. Wischmeyer PE, Jayakar D, Williams U, Singleton KD, Riehm J, Bacha EA, et al. Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. J Parenter Enteral Nutr 2003; 27: 396-403.
39. Khogali SO, Harper AA, Lyall JA, Rennie MJ. Effects of Lglutamine on postischaemic cardiac function: protection and rescue. J Mol Cell Cardiol 1998; 30: 819-27.
40. Khogali SO, Weryk B, Lyall JA, Rennie MJ. Post-ischaemic reperfusion with glutamine, but not glutamate or aspartate, enhances glutathione reduction state in the isolated working rat heart. Proc Phys Soc 1998; 513: 160.
41. Welbourne TC. Ammonia production and glutamine incorporation into glutathione in the fractioning rat kidney. Cancer J Biochem 1979; 59: 629.
42. Cao Y, Kennedy R, Klimberg VS. Glutamine protects against doxorubicin-induced cardiotoxicity. J Surg Res 1999; 85: 178-82.
43. Pisarenko OI, Shul'zhenko VS, Studneva IM, Timoshin AA. Moderation of postischemic damage to cardiomyocytic membranes with reperfusion solution. Bull Exp Biol Med 2007; 143: 15-7.
44. Atahan E, Ergun Y, Belge Kurutas E, Cetinus E, Guney Ergun U. Ischemia-reperfusion injury in rat skeletal muscle is attenuated by zinc aspartate. J Surg Res 2007; 137: 109-16.
45. Ji B, Liu J, Liu M, Feng Z, Wang G, Lu F, et al. Effect of cold blood cardioplegia enriched with potassium-magnesium aspartate during coronary artery bypass grafting. J Cardiovasc Surg 2006; 47: 671-5.
46. Modi P, Suleiman SM, Reeves BC, Pawade A, Parry AJ, Angelini GD, et al. Changes in myocardial free amino acids during pediatric cardiac surgery: a randomised controlled trial of three cardioplegic techniques. Eur J Cardiothorac Surg 2006; 30: 41-8.
47. Ghomeshi HR, Tian G, Ye J, Sun J, Hoffenberg EF, Salerno TA, et al. Aspartate/glutamate-enriched blood does not improve myocardial energy metabolism during ischemia-reperfusion: a 31P magnetic resonance spectroscopic study in isolated pig hearts J Thorac Cardiovasc Surg 1997; 113: 1068-77.
48. Uyar I, Mansuroǧlu D, Kirali K, Erentuǧ V, Bozbuǧa NU, Gülseli Uysal G, et al. Aspartate and glutamate-enriched cardioplegia in left ventricular dysfunction. J Card Surg 2005: 20: 337-44.
49. Odom JE, Kemp GJ, Radda GK. The regulation of total creatine content in a myoblast cell line. Mol Cell Biochem 1996; 158: 179-88.
50. Guerrero-Ontiveros ML, Wallimann T. Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo: Down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem 1998; 184: 427-37.
51. Casey A, Constantin-Teodosiu D, Howell S, Hultman E, Greenhaff PL. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol 1996; 271: E31-7.
52. Gordon A, Hultman, E, Kaijser L. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 1995; 30: 413-18.
53. Horn M, Remkes H, Dienesch C, Hu K, Ertl G, Neubauer S. Chronic high-dose creatine feeding does not attenuate left ventricular remodeling in rat hearts post-myocardial infarction. Cardiovasc res 1999; 43: 117-24.
54. Ferraro S, Codella C, Palumbo F, Desiderio A, Trimigliozzi P, Maddalena G, et al. Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo. Clin Cardiol 1996; 19: 699-703.
55. Woo YJ, Grand TJ, Zentko S, Cohen JE, Hsu V, Atluri P, et al. Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization. J Cardiovasc Surg (Torino) 2005; 46: 297-305.
56. Reznick AK, Kagen VE, Ransey R, Tsuchiya M, Serbinova EA, Packer L, Antiradical effect in L-propionyl carnitine. Protection of the heart against ischemic reperfusion injury. The possible role of ion chelation, Arch Biochem Biophys 1992; 296: 349-401.
57. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem 1992; 267, 3758-63.
58. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618-24.
59. Kelly GS. Insulin resistance: Lifestyle and nutritional interventions, Altern Med Rev 2000; 5: 109-32.
60. Hulsmann WC. Biochemical profile of propionyl-L-carnitine. Cardiovasc Drugs Ther 1991; 5(Suppl I): 7-10.
61. Siliprandi N, Di Lisa F, Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991; 5(Suppl I): 11-5.
62. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischernia is accompanied by a stimulation of glucose oxidation. Circulation 1993; 87: 972-81.
63. Leipala JA, Bhatnagar R, Pineda E, Najibi S, Massoumi K, Packer L. Protection of the reperfused heart by L-propionylcarnitine. J Appl Physiol 1991; 71: 1518-22.
64. Paulson DJ, Traxler J, Schmidt M, Noonan J, Shug AL. Protection of the ischaemic myocardium by propionyl-Lcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc Res 1986; 20: 538-41.
65. Pasini E, Comini L, Ferrari R, de Giuli F, Menotti A, Dalla NS. Effect of propionyl-L-carnitine on experimental induced cardiomyopathy in rats. Am J Cardiovasc Pathol 1992; 4: 216-22.
66. Micheletti R, Schiavone A, English E, Benatti P, Caposso JM, Anversa P, et al: Propionyl-L-carnitine limit chronic ventricular dilatation after myocardial infarction in rats. Am J Physiol 1993; 264: H1111-7.
67. Yang XP, Samaja M, English E, Benatti P, Tarantola M, Cardace G, et al. Hemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure-overload cardiac hypertrophy. J Cardiovasc Pharmacol. 1992; 20: 88-98.
68. Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodinamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998; 12: 291-9.
69. Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995; 26: 380-7.
70. Caponnetto S, Canale C, Masperone MA. Efficacy of propionyl-L-carnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994; 15: 1167-73.
71. The investigators of the study on propionyl-L-carnitine in chronic heart failure. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 1999; 20: 70-6.
72. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J 1996; 72: 45-50.
73. Lesnefsky EJ, He DC, Moghaddas S, Hoppel CL. Reversal of mitochondrial defects before ischemia protects the aged heart. The FASEB J 2006; 20: 1543-5.
74. Paradies GRF, Dinoi P, Petrosillo G, Quagliariello E. Agedependent decrease in the cytochrome c oxidase activity and changes in phopsholiids in rat-heart mitochondria. Arch Gerontol Geriatr 1993; 16: 262-72.
75. Paradies G, Ruggiero FM, Petrosillo G, Gadaleta MN, Quagliariello E. The effect of aging and acetyl-L-carnitine on the function and on the lipid composition of rat heart mitochondria. Ann N Y Acad Sci 1994; 717: 233-43.
76. Paradies G, Ruggiero FM, Petrosillo G, Gadaleta MN, Quagliariello E. Effect of aging and acetyl-L-carnitine on the activity of cytochrome oxidase and adenine nucleotide translocase in rat heart mitochondria. FEBS Lett 1994; 350: 213-5.
77. Vik SB, Capaldi RA. Lipid requirements for cytochrome c oxidase activity. Biochemistry 1977; 16: 5755-9.
78. Gadaleta MN, Petruzzella V, Daddabbo L, Olivieri C, Fracasso F, Loguercio Polosa P, et al. Mitochondrial DNA transcription and translation in aged rat. effect of acetyl-L-carnitine. Ann N Y Acad Sci 1994; 717: 150-60.
79. Gadaleta MN, Petruzzella V, Renis M, Fracasso F, Cantatore P. Reduced transcription of mitochondrial DNA in the senescent rat. Tissue dependence and effect of L-carnitine. Eur J Biochem 1990; 187: 501-6.
80. Krebs HA, JohnsonWA. Metabolism of ketonic acids in animal tissues. Biochem J 1937; 31: 645-51.
81. Braun-Menendez E, Chute AL, Gregory RA. The usage of pyruvic acid by the dogs heart. Quart J Exp Physiol 1939; 29: 91-7.
82. Bunger R, Haddy FJ, Querengasser A, Gerlach E. An isolated guinea pig heart preparation with in vivo like features. Pflugers Arch Eur J Physiol 1975; 353: 317-26.
83. Bunger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Eur J Biochem 1988; 180: 221-33.
84. Mentzer RM, van Wylen DGL, Sodhi J, Weiss RJ, Lasley RD, Willis J, et al. Effect of pyruvate on regional ventricular function in normal and stunned myocardium. Ann Surg 1989; 209: 629-34.
85. Liedtke AJ, Nellis SH. Effect of buffered pyruvate on regional cardiac function in moderate, short-term ischemia in swine heart. Circ Res 1979; 43: 189-99.
86. Liedtke AJ, Nellis SH, Neely JR, Hughes HC. Effects of treatment with pyruvate and tromethamine in experimental myocardial ischemia. Circ Res 1976; 39: 378-87.
87. Yanos J, Patti MJ, Stanko RT. Hemodynamic effects of intravenous pyruvate in the intact, anesthetized dog. Crit Care Med 1994; 22: 844-50.
88. Scholz TD, Laughlin MR, Balaban RS, Kupriyanov VV, Heineman FW. Effect of substrate on mitochondrial NADH, cytosolic redox state, and phosphorylated compounds in isolated hearts. Am J Physiol 1995; 268: H82-91.
89. Martin BJ, Valdivia HH, Bunger R, Lasley RD, Mentzer RM. Pyruvate augments calcium transients and cell shortening in rat ventricular myocytes. Am J Physiol 1998; 274: H8-17.
90. Hermann HP, Zeitz O, Keweloh B, Hasenfuss G, Janssen PML. Pyruvate potentiates inotropic effects of isoproterenol and Ca2+ in rabbit cardiac muscle preparations. Am J Physiol Heart Circ Physiol 2000; 279: H702-8.
91. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure. Lancet 1999; 353: 1321-3.
92. Xiang JZ, Kentish JC. Effects of inorganic phosphate and ADP on calcium handling by the sarcoplasmic reticulum in rat skinned cardiac muscles. Cardiovasc Res 1995; 29: 391-400.
93. Laughlin MR, Heineman FW. The relationship between phosphorylation potential and redox state in the isolated working rat heart. J Mol Cell Cardiol 1994; 26: 1525-31.
94. Deboer LWV, Bekx PA, Han L, Steinke L. Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation. Am J Physiol (Heart Circ Physiol) 1993; 265: H1571-6.
95. Bassenge E, Sommer O, Schwemmer M, Bunger R. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state.AmJ Physiol (Heart Circ Physiol) 2000; 279: H2431-8.
96. Tejero-Taldo MI, Caffrey JL, Sun J, Mallet RT. Antioxidant properties of pyruvate mediate its potentiation of aadrenergic inotropism in stunned myocardium. J Mol Cell Cardiol 1999; 31: 1863-72.
97. Chan W, London R, Murphy E, Steenbergen Ch. Regulation of the Ca2+ gradient across the sarcoplasmic reticulum in perfused rabbit heart. Circ Res 1998; 83: 898-907.
98. Mallet RT, Bunger R. Energetic modulation of cardiac inotropism and sarcoplasmatic reticular calcium uptake. Biochim Biophys Acta 1994; 1224: 22-32.
99. Janssen PML, Siegel U, Datz N, Zeitz O, Hermann HP. Influence of pyruvate on economy of contraction in isolated rabbit myocardium. Eur J Heart Fail 2007; 24: 1753-61.
100. Zima AV, Kockskämper J, Mejia-Alvarez R, Blatter LA. Pyruvate modulates cardiac sarcoplasmic reticulum Ca2+ release in rats via mitochondria-dependent and -independent mechanisms. J Physiol 2003; 550: 765-83.
101. Hasenfuss G, Mulieri, LA, Leavitt BJ, Allen PD, Haeberle JR, Alpert NR. Alteration of contractile function and excitationcontraction coupling in dilated cardiomyopathy. Circ Res 1992; 70: 1225-32.
102. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994; 75: 434-42.
103. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-60.
104. Seiler KS, Kehrer JP, Starnes JW, Exogenous glutathione attenuates stunning following intermittent hypoxia in isolated rat hearts. Free Rad Res 1996; 24: 115-22.
105. Tani M, Effects of anti-free radical agents on Na+, Ca2+, and function in reperfused rat hearts. Am J Physiol 1990; 259: H137-43.
106. Cheung PY, Wang W, Schulz R. Glutathione protects against myocardial ischemia-reperfusion injury by detoxifying peroxynitrite. J Mol Cell Cardiol 2000; 32: 1669-78.
107. Blaschke TF. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol 1999; 47: 261-6.
108. Cooke JP, Tsao PS. Arginine: A New Therapy for Atherosclerosis? Circulation 1997; 95: 311-12.
109. Lerman A, Burnett Jr JC, Higano ST, McKinley LJ, Holmes Jr DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123-8.
110. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-53.
111. Dubois-Randé JL, Zelinsky R, Roudot F, Chabrier PE, Castaigne A, Geschwind H, et al. Effects of infusions of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am J Cardiol 1992; 70: 1269-75.
112. Quyyumi AA, Dakak N, Diodati JG, Gilligan DM, Panza JA, Cannon RO III. Effect of L-arginine on human coronary endotheliumdependent and physiologic vasodilation. J Am Coll Cardiol 1997; 30: 1220-7.
113. Tousoulis D, Davies GJ, Tentolouris C, Crake T, Toutouzas P. Coronary stenosis dilatation induced by L-arginine. Lancet 1997; 349: patients with coronary artery disease on medical management. Circulation 2000; 101: 2160-4.
114. Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, et al. The vascular effects of L-arginine in humans: the role of endogenous insulin. J Clin Invest 1997; 99: 433-8.
115. Nagase S, Takemura K, Ueda A, Hirayama A, Aoyagi K, Kondoh M, et al. A novel nonenzymatic pathway for the generation of nitric oxide by the reaction of hydrogen peroxide and D- or L-arginine. Biochem Biophys Res Commun 1997; 233: 150-3.
116. Maxwell AJ, Zapien MP, Pearce GL, MacCallum G, Stone PH. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol 2002; 39: 37-45.
117. Blum A, Porat R, Rosenschein U, Keren G, Roth A, Laniado S, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol 1999; 83: 1488-90.
118. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331-3.
119. Walker HA, McGing E, Fisher I, Boger RH, Bode-Böger SM, Jackson G, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38: 499-505.
120. Bednarz B, Wolk R, Chamiec T, Herbaczynska-Cedro K, Winek D, Ceremuzynski L. Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol 2000; 75: 205-10.
121. Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94: 130-4.
122. Kaye MD, Parnell MM, Ahlers BA. Reduced myocardial and systemic L-arginine uptake in heart failure. Circ Res 2002; 91: 1198-207.
123. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93, 2135-41.
124. Doutreleau S, Mettauer B, Piquard F, Rouyer O, Schaefer A, Lonsdorfer J, et al. Chronic L-arginine supplementation enhances endurance exercise tolerance in heart failure patients. Int J Sports Med 2006; 2: 567-72.
125. Watanabe G, Tomiyama H, Doba N. Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens 2000; 18: 229-34.
126. Bocchi EA, Vilella de Moraes AV, Esteves-Filho A, Bacal F, Auler JO, Carmona MJ, et al. L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol 2000; 23: 205-10.
127. Hirooka O Y, Imaizumi T, Tagawa T, Shiramoto M, Endo T, Ando S, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 1994; 90, 658-68.
128. Chin-Dusting JP, Ahlers BA, Kaye DM, Kelly JJ, Whitworth JA. L-arginine transport in humans with cortisol-induced hypertension. Hypertension 2003; 41: 1336-40.
129. Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 2000; 102: 2707-12.
130. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Ernst KV, et al. L-arginine therapy in acute myocardial infarction: The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58-64.
131. de Castro Barbosa T, Poyares LL, Machado UF, Nune MN. Chronic oral administration of arginine induces GH gene expression and insulin resistance. Life Sci 2006; 79: 1444-9.
132. Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med 2004; 199: 347-56.
133. Mori M, Gotoh T, Nagasaki A, Takiguchi M, Sonoki T. Regulation of the urea cycle enzyme genes in nitric oxide synthesis. J Inher Metab Dis 1998; 21(Suppl 1): 59-71.
134. Romero MJ, Platt DH, Caldwell RB, Caldwell RW. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006; 24: 275-90.
135. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett 2003; 226: 195-202.
136. Pion PD, Kittleson MD, Rogers QR, Morris JG. Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science 1987; 237: 764-8.
137. Fascetti AL, Reed JR, Rogers QR, Backus RC.Taurine deficiency in dogs with dilated cardiomyopathy: 12 cases. J Am Vet Med Assoc 2003; 223: 1137-41.
138. Schaffer SW, Allo S, Harada H, Mozaffari M. Potentation of myocardial ischemic injury by drug-induced taurine depletion. In: Huxtable RJ, Franconi F, Giotti A, Eds. The biology of taurine. New York: Plenum Press; 1987: 151-8.
139. Crass MF, Lombardini JB. Loss of cardiac muscle taurine after acute left ventricular ischemia. Life Sci 1977; 21: 951-8.
140. Kramer JH, Chovan JP, Schaffer SW. The effect of taurine on calcium paradox and ischemic heart failure. Am J Physiol 1981; 240: H238-46.
141. Azari J, Brumbaugh P, Barbeau A, Huxtable R. Taurine decreases lesion severity in the hearts of cardiomyopathic Syrian hamsters. Can J Neurol Sci 1980; 7: 435-40.
142. Takihara K, Azuma J, Awata N. Beneficial effect of taurine in rabbits with chronic congestive heart failure. Am Heart J 1986; 112: 1278-84.
143. Oudit GY, Trivieri MG, Khaper N, Hussain T, Wilson GJ, Liu P, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron overload murine model. Circulation 2004; 109: 1877-85.
144. Azuma J, Sawamura A, Awata N, Ogura K, Harada H, Yamamura Y, et al. Double-blind randomized crossover trial of taurine in congestive heart failure. Curr Ther Res 1983; 34: 543-57.
145. Tischler ME, Desautels H, Goldberg AL. Does leucine, leucyl-cRNA or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? J Biol Chem 1982; 257: 1613-21.
146. Harper, Miller RH, Lock KP, Branched-chain amino acid metabolism. Annu Rev Nutr 1984; 4: 409-54.
147. Tischler ME, Desautels M, Goldberg AL. Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? J Biol Chem 1982; 257: 1613-21.
148. Rannels DE, Hjalmarson AC, Morgan HE. Effects of noncarbohydrate substrates on protein synthesis in muscle. Am J Physiol 1974; 226: 528-39.
149. Chua BHL, Siehl DL, Morgan HE. A role for leucine in regulation of protein turnover in working rat hearts. Am J Physiol 1980; 239: E510-4.
150. Young LH, McNulty PH, Morgan C, Deckelbaum LI, Zaret BL, Barrett EJ. Myocardial protein turnover in patients with coronary artery disease: effect of branched chain amino acid infusion. J Clin Invest 1991; 87: 554-60.
151. Aquilani R. Oral amino acid administration in patients with diabetes mellitus: supplementation or metabolic therapy? Am J Cardiol 2004; 93: 21-2.
152. Davis TA, Fiorotto ML, Nguyen HV, Reeds PJ. Enhanced response of muscle protein synthesis and plasma insulin to food intake in suckled rats. Am J Physiol Regul Integr Comp Physiol 1993; 265: R334-40.
153. Wang X, Campbell LE, Miller CM, Proud CG. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J 1998; 334: 261-7.
154. Escobar J, Frank JW, Suryawan A, Nguyen HV, Kimball SR, Jefferson LS, et al. Regulation of cardiac and skeletal muscle protein synthesis by individual branched-chain amino acids in neonatal pigs. Am J Physiol Endocrinol Metab 2006; 290: E612-21.
155. Dorfman TA, Levine BD, Tillery T, Peshock RM, Hastings JL, Schneider SM, et al. Cardiac atrophy in women following bed rest Scand J Med Sci Sports 2007; 5: 611-12.
156. Scognamiglio R, Piccolotto R, Negut C, Tiengo A, Avogaro A. Oral amino acids in elderly subjects: effect on myocardial function and walking capacity. Gerontology 2005; 51: 302-8.
157. Arslan F, de Kleijn DP, Timmers L, Doevendans PA, Pasterkamp G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des 2008; 14(12): 1205-16.
158. Kuhl M, Lip GY, Varma C. Management of hypertension in relation to acute coronary syndromes and revascularisation. Curr Pharm Des 2007; 13(25): 2556-66.
159. Sahuquillo J, Vilalta A. Cooling the injured brain: how does moderate hypothermia influence the pathophysiology of traumatic brain injury. Curr Pharm Des 2007; 13(22): 2310-22.